Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag plus immunosuppressive therapy for severe hepatitis-related aplastic anemia in children
ChiCTR2200057674Phase 4Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avatrombopag in Hepatitis-associated aplastic anemia (HAAA), sponsored by Capital Medical University. Primary endpoint: Complete response rate at 6 months. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
avatrombopag
03
Conditions
Hepatitis-associated aplastic anemia (HAAA)
Beyond the preview
Go deeper on ChiCTR2200057674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057674.